Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.
Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.
The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.
Belgian Nanobody drug developer Ablynx says it will be transformed by positive Phase III topline HERCULES data on caplacizumab for treating the rare blood-clotting disorder, acquired TTP.
The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.
Three-year-old clinical-stage UK biotech Autolus will use its $80m (£59m) Series C financing to advance three dual targeting CAR-T candidates in the clinic and build capacity.